How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Prefilled Vaccine Syringes Market
- By Vaccine Type: Influenza Vaccine, COVID-19 Vaccine, Hepatitis B Vaccine, MMR Vaccine (Measles, Mumps, Rubella), Tetanus Vaccine
- By Material Type: Glass Prefilled Syringes, Plastic Prefilled Syringes, Polymer Prefilled Syringes
- By Needle Type: Fixed Needle Syringes, Needle Shield Syringes, Needleless Syringes
- By End User: Hospitals, Clinics, Vaccination Centers, Pharmacies
- By Filling Technology: Aseptic Filling, Blow-Fill-Seal (BFS) Filling, Liquid Filling
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Influenza Vaccine leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Prefilled Vaccine Syringes Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 5
Material Type 3
Needle Type 3
End User 4
Filling Technology 3
Companies profiled
BD (Becton
Dickinson and Company)
Gerresheimer AG
SCHOTT AG
Nipro Corporation
Ompi (Stevanato Group)
West Pharmaceutical Services Inc.
Terumo Corporation
Nexgen Packaging Inc.
SiO2 Medical Products Inc.
Ypsomed AG
Catalent Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BD (Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Dickinson and Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Gerresheimer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →SCHOTT AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Ompi (Stevanato Group)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →West Pharmaceutical Services Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Nexgen Packaging Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →SiO2 Medical Products Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Ypsomed AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Catalent Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →AptarGroup Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Vetter Pharma International GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →SCHOTT Kaisha Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Noble International Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,471M by 2033 · 6.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Influenza Vaccine52.0
- COVID-19 Vaccine6.0
- Hepatitis B Vaccine16.1
- MMR Vaccine (Measles, Mumps, Rubella)13.9
- Tetanus Vaccine11.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,076M → $1,633M · 5.4%
Europe$749.9M → $1,197M · 6.0%
Asia Pacific$684.7M → $1,282M · 8.2%
Latin America$423.9M → $687.1M · 6.2%
Middle East and Africa$326.1M → $502.7M · 5.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.632026
6.642027
6.662028
6.672029
6.682030
6.692031
6.722032
6.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BD (Becton20.6
- Dickinson and Company)17.2
- Gerresheimer AG6.8
- SCHOTT AG12.8
- Nipro Corporation8.1
- Ompi (Stevanato Group)6.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type8.5%
Material Type25.5%
Needle Type21.8%
End User19.8%
Filling Technology24.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.8
- Europe22.6
- Asia Pacific24.2
- Latin America13.0
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BD (Becton | 92 | 92 | 92 | 91 | 98 | 74 | 90 |
| Dickinson and Company) | 76 | 84 | 82 | 68 | 69 | 73 | 75 |
| Gerresheimer AG | 73 | 77 | 76 | 84 | 87 | 64 | 77 |
| SCHOTT AG | 60 | 57 | 81 | 63 | 60 | 82 | 67 |
| Nipro Corporation | 76 | 76 | 58 | 62 | 63 | 63 | 66 |
| Ompi (Stevanato Group) | 67 | 67 | 50 | 47 | 51 | 50 | 55 |
| West Pharmaceutical Services Inc. | 42 | 50 | 41 | 43 | 48 | 43 | 45 |
| Terumo Corporation | 41 | 46 | 47 | 50 | 49 | 54 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BD (Becton
- Dickinson and Company)
- Gerresheimer AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BD (Becton | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Dickinson and Company) | ◐ | ◐ | ◐ | − | − | ◐ |
| Gerresheimer AG | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| SCHOTT AG | ◐ | ◐ | ✓ | ✓ | − | ◐ |
| Nipro Corporation | ◐ | ◐ | − | − | ◐ | ◐ |
| Ompi (Stevanato Group) | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| West Pharmaceutical Services Inc. | ◐ | ◐ | ◐ | ◐ | − | − |
| Terumo Corporation | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BD (Becton90
2Gerresheimer AG77
3Dickinson and Company)75
4SCHOTT AG67
5Nipro Corporation66
6Ompi (Stevanato Group)55
7Terumo Corporation48
8West Pharmaceutical Services Inc.45
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
BD (Becton
Challenger3
Strong scale, closing on the leaders.
Dickinson and Company)Gerresheimer AGSCHOTT AG
Contender1
Focused players with pockets of strength.
Nipro Corporation
Niche3
Specialists in a single segment or region.
Ompi (Stevanato Group)West Pharmaceutical Services Inc.Terumo Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vaccine Type in North America, then scale across Prefilled Vaccine Syringes Market — a $558M beachhead inside a $7.74B market.
Beachhead (SOM)$558Mobtainable near-term
Serviceable (SAM)$3.18Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Influenza Vaccine
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer79 fit
COVID-19 Vaccine
Strong fit — clear ROI and a fast path to value.
End user65 fit
Hepatitis B Vaccine
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Material Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Needle Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Prefilled Vaccine Syringes Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified25%
Evaluation12%
Closed-won6%
$10.4KCAC
$51KLTV
4.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Prefilled Vaccine Syringes Market is a high-growth opportunity — $7.54B by 2033, compounding at 10.0%.
TAM · 2025$3.51Btoday
TAM · 2033$7.54Bforecast
CAGR10.0%2027–2033
Cumulative$47.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.54BTotal addressable market
SAM$2.71BServiceable available market
SOM$497MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.0% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.54BLarge & growingTAM by 2033 at 10.0% CAGR
$2.71BServiceable nowreachable with today’s model
$497MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.88BBear6.5% CAGR
$7.54BBase10.0% CAGR
$9.66BBull13.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Material Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Prefilled Vaccine Syringes Market — a $3.27B market by 2033. Plan: grow share from 8.4% to 15.6%.
Market size · 2033$3.27Btotal addressable
Market CAGR5.6%2027–2033
Target share15.6%from 8.4% today
Revenue ambition$510Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 15.6% | At risk |
| Revenue | $261M | $510M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.1% | 41.8% | At risk |
| Customer retention | 91.9% | 96.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Material Type capability
A defensible second engine — invest in Material Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Material Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $74M capacity & capability investment
- Greenlight bolt-on M&A in Material Type
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Prefilled Vaccine Syringes Market conversation — a $5.42B market you can size, segment and defend in minutes.
Market size · 2033$5.42Btotal opportunity
Growth10.8%CAGR to 2033
Addressable buyers983+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 3 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
BD (BectonDickinson and Company)Gerresheimer AGSCHOTT AGNipro CorporationOmpi (Stevanato Group)West Pharmaceutical Services Inc.Terumo Corporation+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Prefilled Vaccine Syringes Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Prefilled Vaccine Syringes Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Prefilled Syringe with Safety Device Market
Market size, share, segmentation and regional forecast.
$672M market · 2025 base year
View reportPrefilled Syringes Drug Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportPrefilled Syringe Plungers Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportPre Filled Syringe (PFS) Filling and Stoppering Machines Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportPrefilled Syringe Filling Machines Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportPre-filled Syringe Filling Machines for Biological Preparations Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportPre Filled Syringe Filling and Stoppering Machine Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportPrefilled Syringe Barrels Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportPre Filled Syringe Assembly Market
Market size, share, segmentation and regional forecast.
$999M market · 2025 base year
View reportPrefilled Syringe and Disposable Syringes Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportPrefilled Syinges Market
Market size, share, segmentation and regional forecast.
$505M market · 2025 base year
View reportPrefilled Sterile Water Syringes Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.